Fuzapladib in Dogs

Fuzapladib is a prescription injectable medication used in dogs for the management of clinical signs associated with acute onset pancreatitis. In the United States, it is marketed as PANOQUELL®-CA1 and is given by your vet in-clinic, not at home. It is meant to be part of a broader treatment plan, not a stand-alone cure. Dogs with pancreatitis often still need IV fluids, pain relief, anti-nausea medication, diet support, and close monitoring.

This drug is notable because pancreatitis care in dogs has traditionally focused on supportive treatment rather than a pancreas-targeted medication. Fuzapladib was developed to reduce inflammatory cell activity that may worsen pancreatic injury. In a 2023 randomized controlled study in client-owned dogs with presumptive acute pancreatitis, dogs receiving fuzapladib showed greater improvement in clinical activity scores over three days than dogs receiving placebo, and the drug was reported to be well tolerated. That said, the study did not show whether it improves survival or shortens hospitalization, so expectations should stay realistic.

In the U.S., PANOQUELL®-CA1 has been marketed under FDA conditional approval rather than full approval. That means the FDA determined the drug is safe and has a reasonable expectation of effectiveness for its labeled use, while additional effectiveness data are still being collected. For pet parents, the practical takeaway is that your vet may consider it as one option for acute pancreatitis, especially when the goal is to add a targeted anti-inflammatory approach to standard supportive care.

Because pancreatitis ranges from mild nausea and belly pain to shock and organ complications, fuzapladib is not right for every dog. Your vet will weigh your dog’s age, overall stability, other diseases, current medications, and whether hospitalization is needed. See your vet immediately if your dog has repeated vomiting, severe lethargy, abdominal pain, collapse, or trouble breathing.

Fuzapladib works by inhibiting activation of LFA-1, a molecule involved in neutrophil adhesion and migration. Neutrophils are white blood cells that help drive inflammation. In acute pancreatitis, inflammatory cell movement into pancreatic tissue is thought to contribute to local damage and the wider inflammatory response. By reducing that process, fuzapladib may help lessen the severity of clinical signs.

This mechanism is different from medications that mainly control symptoms, such as anti-nausea drugs or pain medications. Fuzapladib is aimed at one part of the inflammatory cascade, while other pancreatitis treatments address dehydration, vomiting, pain, electrolyte imbalance, and nutrition. That is why your vet will usually use it as an add-on therapy rather than a replacement for supportive care.

The labeled canine dose is given once daily for three consecutive days by IV bolus injection. Improvement may be seen within about 24 hours in some dogs, but response varies with disease severity and with how early treatment starts. A dog with mild pancreatitis may improve quickly, while a dog with systemic illness may still need several days of hospitalization even if fuzapladib is included.

It is also important to understand what fuzapladib does not do. It does not remove the underlying trigger for pancreatitis, and it does not replace diagnostics or monitoring. Dogs may still need bloodwork, pancreatic lipase testing, imaging, and repeated exams so your vet can track hydration, pain, appetite, liver values, and any complications.

Reported side effects and adverse reactions with fuzapladib include appetite loss, digestive tract signs, respiratory tract signs, hepatopathy, and jaundice. VCA also lists regurgitation, vomiting or nausea, coughing, trouble breathing, diarrhea, and yellowing of the skin or whites of the eyes as potential concerns to watch for after treatment. Because dogs receiving this medication already have pancreatitis, some of these signs can overlap with the disease itself. That can make monitoring more nuanced.

In safety information from the product materials, injection-site swelling and bruising, mild thrombocytopenia, and hypertension were also observed in a nine-day target animal safety study at labeled and higher doses. The labeled course is shorter, once daily for three days, but these findings still matter because they help your vet think through monitoring and risk. If your dog is hospitalized, the team can watch for changes in comfort, breathing, appetite, blood pressure, and lab values.

Some dogs may be at higher risk for problems or may not be ideal candidates. The safe use of fuzapladib has not been evaluated in puppies under 6 months, breeding dogs, pregnant or nursing dogs, or dogs with cardiac disease, hepatic failure, or renal impairment. Dogs with a known hypersensitivity to fuzapladib should not receive it.

See your vet immediately if your dog develops worsening vomiting, marked lethargy, yellow discoloration of the eyes or gums, coughing, labored breathing, collapse, or swelling around the injection area. Even when a reaction turns out to be mild, quick communication helps your vet decide whether your dog needs recheck bloodwork, supportive care, or a change in the treatment plan.

Fuzapladib is administered by your vet as an intravenous injection. The labeled dose for dogs is 0.4 mg/kg, which equals 0.1 mL/kg after reconstitution to a 4 mg/mL solution. It is given once daily for three consecutive days as an IV bolus over about 15 seconds to 1 minute. This is an in-clinic medication, so pet parents do not usually give it at home.

Because the drug is supplied as a lyophilized powder with a specific diluent, proper reconstitution and handling matter. Product information states that no other diluent should be used. Once reconstituted, the vial is refrigerated and remains stable for 28 days, which can help clinics reduce waste when treating multiple patients.

Most dogs receiving fuzapladib are being treated for acute pancreatitis at the same time, so administration is usually coordinated with other hospital care. Your vet may place a peripheral IV catheter, use a butterfly catheter, or administer the dose directly by syringe. The medication should not be diluted into an IV fluid bag for administration.

There is no universal home dosing schedule because this is not an oral medication for routine use. If your dog is discharged before all three doses are completed, your vet will tell you whether to return for the remaining injections and what monitoring is needed between visits. Never adjust the dose or timing on your own. Dogs with pancreatitis can change quickly, and treatment decisions should be based on recheck exams and response to care.

Published interaction data for fuzapladib are still limited. VCA notes that formal drug interactions have not been reported, but the medication may have the potential to increase blood levels of other drugs. Product materials also state that fuzapladib is highly protein bound and that use with other highly protein bound medications has not been studied in dogs. That does not mean a combination is always unsafe. It means your vet should review the full medication list carefully.

One especially important caution is concurrent NSAID use. VCA specifically advises against use in dogs receiving non-steroidal anti-inflammatory drugs such as meloxicam or robenacoxib. In pancreatitis cases, many dogs are managed with opioid pain relief, anti-nausea medications, gastroprotectants, fluids, and sometimes antibiotics or other supportive drugs instead. Your vet will choose combinations based on your dog’s hydration, kidney and liver values, stomach comfort, and overall risk profile.

According to VCA, some medications were used at the same time in safety work without obvious adverse effects, including pain medications other than NSAIDs, anti-vomiting medications, antiparasite medications, vaccines, and drugs for well-controlled preexisting conditions. Even so, that should not be taken as a blanket clearance for every combination. A dog with pancreatitis may also have diabetes, kidney disease, heart disease, or liver changes that affect medication choices.

Before treatment, tell your vet about every prescription, over-the-counter product, supplement, and herbal item your dog receives. That includes fish oil, CBD products, joint supplements, and flea or tick preventives. Small details can matter when your dog is sick enough to need pancreatitis care.